Skip to main content
SpringerLink
Log in

Anti-CTLA-4 Ab

  • Chapter
  • First Online:
Immunotherapy of Cancer

Abstract

Ipilimumab (MDX-010, BMS-734016) is a fully human monoclonal immunoglobulin (IgG1) specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152), which is expressed on a subset of activated T cells as a negative regulator of T-cell activation. Two phase III clinical studies (MDX010-20 and CA184-024) of ipilimumab have demonstrated a clinically meaningful and statistically significant survival benefit in pretreated advanced melanoma and previously untreated advanced melanoma, respectively (Hodi FS et al., N Engl J Med 363:711–723, 2010; Robert C et al., N Engl J Med 364:2517–2526, 2011). Ipilimumab (Yervoy™) has been approved for clinical use in advanced melanoma in over 40 countries as the first immune checkpoint inhibitor to show overall survival benefit in patients with advanced melanoma. From the experiences in both clinical development and clinical use of ipilimumab in more than 18,000 patients, some unique features of ipilimumab such as response patterns, durability of response, long-term survival benefit, immune-related adverse events (irAEs), and their management have been recognized. Challenges that contribute to the further development of ipilimumab are currently underway, including combination therapies and biomarker research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bretscher P et al (1970) A theory of self-nonself discrimination. Science 169:1042–1049

    Article  CAS  PubMed  Google Scholar 

  2. Lenschow DJ et al (1996) CD28/B7 system of T-cell costimulation. Annu Rev Immunol 14:233–258

    Article  CAS  PubMed  Google Scholar 

  3. Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  CAS  PubMed  Google Scholar 

  6. Brunet JF, Denizot F, Luciani MF et al (1987) A new member of the immunoglobulin superfamily – CTLA-4. Nature 328:267–270

    Article  CAS  PubMed  Google Scholar 

  7. Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201–210

    Article  CAS  PubMed  Google Scholar 

  8. Kearney ER, Walunas TL, Karr RW et al (1995) Antigen-dependent clonal expansion of a trace population of antigen- specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 155(3):1032–1036

    CAS  PubMed  Google Scholar 

  9. Krummel MF et al (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465

    Article  CAS  PubMed  Google Scholar 

  10. Krummel MF et al (1996) Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8(4):519–523

    Article  CAS  PubMed  Google Scholar 

  11. Walunas TL et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5):405–413

    Article  CAS  PubMed  Google Scholar 

  12. Perez VL, Van Parijs L, Biuckians A et al (1997) Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411–417

    Article  CAS  PubMed  Google Scholar 

  13. Chambers CA et al (1997) Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7(6):885–895

    Article  CAS  PubMed  Google Scholar 

  14. Tivol EA et al (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541–547

    Article  CAS  PubMed  Google Scholar 

  15. Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238):985–988

    Article  CAS  PubMed  Google Scholar 

  16. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611–618

    Article  CAS  PubMed  Google Scholar 

  17. Yang YF, Zou JP, Mu J et al (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57(18):4036–4041

    CAS  PubMed  Google Scholar 

  18. McGaha T, Murphy JW (2000) CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun 68(8):4624–4630

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Gomes NA, Barreto-de-Souza V, Wilson ME et al (1998) Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. J Infect Dis 178(6):1847–1851

    Article  CAS  PubMed  Google Scholar 

  20. Riley JL, Schlienger K (2000) Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 191(11):1987–1997

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Read S et al (2006) Blockage of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177(7):4376–4383

    Article  CAS  PubMed  Google Scholar 

  22. Wing K (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275

    Article  CAS  PubMed  Google Scholar 

  23. Selby et al (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T. cells. Cancer Immunol Res 1:32–42

    Article  CAS  PubMed  Google Scholar 

  24. Simpson et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Liakou et al (2008) CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105:14987–14992

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Camacho LH, Antonia S, Sosman J et al (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075–1081

    Article  CAS  PubMed  Google Scholar 

  28. Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616–622

    Article  CAS  PubMed  Google Scholar 

  29. National comprehensive cancer network clinical practice guidelines in oncology melanoma, version 3.2014

    Google Scholar 

  30. Dummer R, Hauschild A, Guggenheim M et al (2012) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Supplement 7):vii86–vii91

    PubMed  Google Scholar 

  31. Kwon ED et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 14:700–712

    Article  Google Scholar 

  32. Lynch TJ et al (2046) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2012

    Google Scholar 

  33. Reck M et al (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive disease small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75–83

    Article  CAS  PubMed  Google Scholar 

  34. Nokihara H Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer. Presented at: IASLC 15th world conference on lung cancer

    Google Scholar 

  35. Ipilimumab Investigator Brochure Ver.16.

    Google Scholar 

  36. Maio M, Bondarenko I, Robert C et al Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine on phase III study CA184-024. ESMO 2012, Abstract 1127

    Google Scholar 

  37. Eggermont AM et al (2014) Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO 2014, LBA9008

    Google Scholar 

  38. Saenger YM et al (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1

    PubMed Central  PubMed  Google Scholar 

  39. Wolchok JD et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420

    Article  CAS  PubMed  Google Scholar 

  40. Maio M et al (2013) Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. Oral presentation ESMO 2013, Abstract 3704

    Google Scholar 

  41. Schadendorf D, Hodi FS, Robert C et al (2013) Late breaking abstract: pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. ECCO Amsterdam, LBA24

    Google Scholar 

  42. Prieto PA et al (2012) CTLA-4 blockade with ipilimumab: long term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039–2047

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. YERVOY™ (ipilimumab) immune-mediated adverse reaction management guide. Available at: https://www.hcp.yervoy.com/pages/index.aspx. Accessed 9 Oct 2014

  44. Giuseppina DVS et al (2014) Onco Targets Ther 7:203–209

    Google Scholar 

  45. Weber JS et al (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697

    Article  CAS  PubMed  Google Scholar 

  46. Ribas A, Hodi FS, Callahan M et al (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:1365–1366

    Article  CAS  PubMed  Google Scholar 

  47. Wolchok JD et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicenter, phase II, dose-ranging study. Lancet Oncol 11:155–164

    Article  CAS  PubMed  Google Scholar 

  48. Puzanov I, Callahan MK, Linette GP et al (2014) 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol 32(suppl 5S):abstr 2511

    Google Scholar 

  49. Kaufman HL, Kirkwood JM, Hodi FS et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588–598

    Article  CAS  PubMed  Google Scholar 

  50. Wolchok JD et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

    Article  CAS  PubMed  Google Scholar 

  51. Sznol M, Kluger HM, Callahan MK et al (2014) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO 4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 32(suppl 5S):abstr LBA9003

    Google Scholar 

  52. Hammers HJ, Plimack ER, Infante JR et al (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32(suppl 5S):abstr 4504

    Google Scholar 

  53. Hodi FS, Lee SJ, McDermott DF et al (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312(17):1744–1753

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Puzanov I, Milhem MM, Andtbacka RHI et al (2014) Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB–IV melanoma. J Clin Oncol 32(suppl 5S):abstr 9029

    Google Scholar 

  55. Dhodapkar MV, Sznol M, Zhao B et al (2014) Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 6:232ra51

    Article  PubMed  Google Scholar 

  56. Neyns B, Wilgenhof S, Corthals J et al (2014) Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 32(suppl 5S):abstr 3014

    Google Scholar 

  57. Gibney GT, Hamid O, Gangadhar TC et al (2014) Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 32(suppl 5s):abstr 3010

    Google Scholar 

  58. Barker CA, Postow MA, Khan SA et al (2013) Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1:92–98

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Barker CA et al (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–997

    Article  PubMed Central  PubMed  Google Scholar 

  60. Lutzky J, Wolchok J, Hamid O et al (2009) Association between immune-related adverse events and disease control or overall survival in patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27:abstr 9034

    Google Scholar 

  61. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Berman DM et al (2009) Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients with advanced melanoma treated with ipilimumab. J Clin Oncol 27:15s

    Article  Google Scholar 

  63. Postow MA, Chasalow SD, Yuan J et al (2013) Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J Clin Oncol 31(suppl):abstr 9052

    Google Scholar 

  64. Tang DN, Shen Y, Yuan J et al (2013) Increased frequency of ICOSt CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1:229–234

    Article  PubMed Central  CAS  Google Scholar 

  65. Yuan J et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108:16723–16728

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Kitano S, Postow M, Yuan J et al (2012) Myeloid derived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg predicts for clinical benefit and improved overall survival in patients with metastatic melanoma. J Clin Oncol 30, (suppl; abstr 2518)

    Google Scholar 

  67. Yuan J, Zhou J, Dong Z et al (2014) Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2:127–132

    Article  CAS  PubMed  Google Scholar 

  68. Hamid O et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Ji RR et al (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019–1031

    Article  CAS  PubMed  Google Scholar 

  70. van Rooij N, van Buuren MM, Philips D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439–e442

    Article  PubMed  Google Scholar 

  71. Charen AS, Makarov V, Merghoub T et al (2014) The neoantigen landscape underlying clinical response to ipilimumab. J Clin Oncol 32(suppl 5S):abstr 3003

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bristol-Myers K.K. Research and Development, 6-5-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 163-1328, Japan

    Takuto Tokudome

Authors
  1. Takuto Tokudome
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuto Tokudome .

Editor information

Editors and Affiliations

  1. Department of Clinical Oncology, Kawasaki Medical School, Okayama, Japan

    Yoshiyuki Yamaguchi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Tokudome, T. (2016). Anti-CTLA-4 Ab. In: Yamaguchi, Y. (eds) Immunotherapy of Cancer. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55031-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55031-0_18

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55030-3

  • Online ISBN: 978-4-431-55031-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation